SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations

References

• World Health Organization. WHO coronavirus (COVID-19) dashboard; 2021. Available from: https://covid19.who.int/. Accessed July 31, 2021.
   Google Scholar
• Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12(3):e7423–e7423. doi:10.7759/cureus.7423
   PubMed Web of Science ®Google Scholar
• Zakhartchouk AN, Sharon C, Satkunarajah M, et al. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine. 2007;25(1):136–143. doi:10.1016/j.vaccine.2006.06.084
   PubMed Web of Science ®Google Scholar
• Yang J, Petitjean SJL, Koehler M, et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun. 2020;11(1):4541. doi:10.1038/s41467-020-18319-6
   PubMed Web of Science ®Google Scholar
• Ou J, Zhou Z, Dai R, et al. V367F mutation in SARS-CoV-2 spike RBD emerging during the early transmission phase enhances viral infectivity through increased human ACE2 receptor binding affinity. J Virol. 2020;95(16):e00617–e00621. doi:10.1128/JVI.00617-21
   Web of Science ®Google Scholar
• Jangra S, Ye C, Rathnasinghe R, et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe. 2021;2(7):e283–e284. doi:10.1016/S2666-5247(21)00068-9
   PubMedGoogle Scholar
• Greaney AJ, Loes AN, Crawford KHD, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3):463–476.e466. doi:10.1016/j.chom.2021.02.003
   PubMed Web of Science ®Google Scholar
• Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proc Natl Acad Sci U S A. 2021;118(36). doi:10.1073/pnas.2103154118
   Web of Science ®Google Scholar
• Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9. doi:10.7554/eLife.61312
   PubMed Web of Science ®Google Scholar
• Liu Z, VanBlargan LA, Bloyet L-M, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29(3):477–488.e474. doi:10.1016/j.chom.2021.01.014
   PubMed Web of Science ®Google Scholar
• World Health Organization. Tracking SARS-CoV-2 variants; 2021. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed July 31, 2021.
   Google Scholar
• Center for Viral Systems Biology. S:E484K mutation report. Outbreak.info; 2021. Available from: https://outbreak.info/situation-reports?pango&muts=S%3AE484K. Accessed July 31, 2021.
   Google Scholar
• Fowler DM, Fields S. Deep mutational scanning: a new style of protein science. Nat Methods. 2014;11(8):801–807. doi:10.1038/nmeth.3027
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–424. doi:10.1038/s41579-021-00573-0
   PubMed Web of Science ®Google Scholar
• Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592(7855):616–622. doi:10.1038/s41586-021-03324-6
   PubMed Web of Science ®Google Scholar
• Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639–644. doi:10.1038/s41586-021-03207-w
   PubMed Web of Science ®Google Scholar
• Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717–726. doi:10.1038/s41591-021-01294-w
   PubMed Web of Science ®Google Scholar
• Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622–625. doi:10.1038/s41591-021-01285-x
   PubMed Web of Science ®Google Scholar
• Collier DA, De Marco A, Ferreira IA, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593(7857):136–141. doi:10.1038/s41586-021-03412-7
   PubMed Web of Science ®Google Scholar
• Glaeser RM. How good can cryo-EM become? Nat Methods. 2016;13(1):28–32. doi:10.1038/nmeth.3695
   Web of Science ®Google Scholar
• Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682–687. doi:10.1038/s41586-020-2852-1
   PubMed Web of Science ®Google Scholar
• World Health Organization. Draft landscape of COVID-19 candidate vaccines; 2021. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed June 29, 2021.
   Google Scholar
• Connors M, Graham BS, Lane HC, Fauci AS. SARS-CoV-2 vaccines: much accomplished, much to learn. Ann Intern Med. 2021;174(5):687–690. doi:10.7326/m21-0111
   Web of Science ®Google Scholar
• Wu K, Werner AP, Koch M, et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med. 2021;384(15):1468–1470. doi:10.1056/NEJMc2102179
   PubMed Web of Science ®Google Scholar
• Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885–1898. doi:10.1056/NEJMoa2102214
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–2383.e2379. doi:10.1016/j.cell.2021.03.013
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021;384(15):1466–1468. doi:10.1056/NEJMc2102017
   PubMed Web of Science ®Google Scholar
• Shen X, Tang H, Pajon R, et al. Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351. N Engl J Med. 2021;384(24):2352–2354. doi:10.1056/NEJMc2103740
   Web of Science ®Google Scholar
• Alter G, Yu J, Liu J, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021;596(7871):268–272. doi:10.1038/s41586-021-03681-2
   PubMed Web of Science ®Google Scholar
• Huang B, Dai L, Wang H, et al. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv. 2021. doi:10.1101/2021.02.01.429069
   Google Scholar
• Zhang X, Yu X, Wei D, et al. Neutralizing Activity of BBIBP-Corv Vaccine-Elicited Sera Against Multiple SARS-Cov-2 Variants of Concern. Research Square; 2021.
   Google Scholar
• Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 variants and vaccines. N Engl J Med. 2021;385(2):179–186. doi:10.1056/NEJMsr2105280
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385(2):187–189. doi:10.1056/NEJMc2104974
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. doi:10.1056/NEJMoa2101544
   PubMed Web of Science ®Google Scholar
• Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385:1172–1183. doi:10.1056/NEJMoa2107659
   PubMed Web of Science ®Google Scholar
• Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899–1909. doi:10.1056/NEJMoa2103055
   PubMed Web of Science ®Google Scholar
• American Society for Microbiology. COVID-19 vaccine breakthrough infections: microbial minutes; 2021. Available from: https://asm.org/Videos/COVID-19-Vaccine-Breakthrough-Infections-Microbial. Accessed June 10, 2021.
   Google Scholar
• Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384(23):2212–2218. doi:10.1056/NEJMoa2105000
   PubMed Web of Science ®Google Scholar
• McEwen AE, Cohen S, Bryson-Cahn C, et al. Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State. Clin Infect Dis. 2021. doi:10.1093/cid/ciab581
   Web of Science ®Google Scholar
• Kustin T, Harel N, Finkel U, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021;27(8):1379–1384. doi:10.1038/s41591-021-01413-7
   PubMed Web of Science ®Google Scholar
• Philomina JB, Jolly B, John N, et al. Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India. J Infect. 2021;83(2):237–279. doi:10.1016/j.jinf.2021.05.018
   Web of Science ®Google Scholar
• Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385:1474–1484. doi:10.1056/NEJMoa2109072
   PubMed Web of Science ®Google Scholar
• Bouton TC, Lodi S, Turcinovic J, et al. COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination strain sequences among healthcare workers at an urban academic medical center: a prospective cohort study. medRxiv. 2021. doi:10.1101/2021.03.30.21254655
   Google Scholar
• Jacobson KB, Pinsky BA, Rath MEM, et al. Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center. medRxiv. 2021. doi:10.1101/2021.04.14.21255431
   Google Scholar
• Thompson CN, Hughes S, Ngai S, et al. Rapid emergence and epidemiologic characteristics of the SARS-CoV-2 B.1.526 variant - New York City, New York, January 1–April 5, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(19):712–716. doi:10.15585/mmwr.mm7019e1
   Web of Science ®Google Scholar
• National Institutes of Health. COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines; 2021. Available from: https://www.covid19treatmentguidelines.nih.gov/. Accessed July 8, 2021.
   Google Scholar
• Min L, Sun Q. Antibodies and vaccines target RBD of SARS-CoV-2. Front Mol Biosci. 2021;8:671633. doi:10.3389/fmolb.2021.671633
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. New data show treatment with Lilly’s neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent; 2021. Available from: https://investor.lilly.com/news-releases/news-release-details/new-data- show-treatment-lillys-neutralizing-antibodies(2021). Accessed January 26, 2021.
   Google Scholar
• Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of bamlanivimab and etesevimab; 2021. Available from: https://www.fda.gov/media/145802/download. Accessed May 14, 2021.
   Google Scholar
• Jensen B, Luebke N, Feldt T, et al. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. Lancet Region Health. 2021;8. doi:10.1016/j.lanepe.2021.100164
   Google Scholar
• Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science (New York, NY). 2020;369(6506):1014–1018. doi:10.1126/science.abd0831
   Google Scholar
• Starr TN, Greaney AJ, Addetia A, et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science (New York, NY). 2021;371(6531):850–854. doi:10.1126/science.abf9302
   Google Scholar
• Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of sotrovimab; 2021. Available from: https://www.fda.gov/media/149534/download. Accessed June 01, 2021.
   Google Scholar
• AstraZeneca. AstraZeneca to supply the US with up to half a million additional doses of the potential COVID-19 antibody treatment AZD7442; 2021. Available from: https://www.astrazeneca.com/media-centre/press-releases/2021/us-supply-agreement-for-additional-azd7442-doses.html#!. Accessed March 16, 2021.
   Google Scholar
• Diamond M, Chen R, Xie X, et al. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Res Square. 2021. doi:10.21203/rs.3.rs-228079/v1
   Google Scholar
• Dong J, Zost SJ, Greaney AJ, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat Microbiol. 2021;6(10):1233–1244. doi:10.1038/s41564-021-00972-2
   PubMed Web of Science ®Google Scholar
• Ryu DK, Song R, Kim M, et al. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochem Biophys Res Commun. 2021;566:135–140. doi:10.1016/j.bbrc.2021.06.016
   PubMed Web of Science ®Google Scholar
• Moderna. Moderna announces positive initial booster data against SARS-CoV-2 variants of concern; 2021. Available from: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-initial-booster-data-against-sars-cov/. Accessed May 05, 2021.
   Google Scholar
• Novavax. Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 phase 3 trial; 2021. Available from: https://ir.novavax.com/2021-06-14-Novavax-COVID-19-Vaccine-Demonstrates-90-Overall-Efficacy-and-100-Protection-Against-Moderate-and-Severe-Disease-in-PREVENT-19-Phase-3-Trial. Accessed June 25, 2021.
   Google Scholar
• Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184(9):2348–2361.e2346. doi:10.1016/j.cell.2021.02.037
   PubMed Web of Science ®Google Scholar